Case 2: 40-year-old Woman with Long-standing HIV Infection

Slides:



Advertisements
Similar presentations
Single Pill HIV Regimens – Introducing the Quad Pedro Cahn, MD Jean-Pierre Routy, MD Calvin Cohen, MD.
Advertisements

Hopital Pitié Salpérière
Management of ARV 6th Advanced HIV Course, Montpellier, September 3-5, 2008 Jürgen Rockstroh, Department of Medicine I, University of Bonn, Germany.
Institute of Clinical Infectious Diseases. Catholic University, Rome
Management of ART in Albania : From the European Guidelines to the real practice. Arjan Harxhi MD, MSc, PhD University Hospital Center of Tirana Mother.
Rational Drug Use Supported by USAID Prescribing, Dispensing, Counseling and Adherence in ART Programs.
Presented by JJ Eron, Jr, MD, IAS, July 25, Special Considerations: When and What to Start with Viral Hepatitis Coinfections Joseph J. Eron, Jr,
Guidelines for Antiviral Treatment of Adults and Adolescents with HIV-1 (including changes, and a little extra on what else is new and current)
Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.
Slide #1 Case Study Objectives: Darrel At the conclusion of this case study, learners will be better able to: Predict challenges to HIV care and treatment.
1 M&E and ART programme Sri Lanka. 2 Overview of the presentation 1.NSACP service delivery points 2.Reporting units of ART programme 3.Recording and reporting.
Innovative Strategies for the Management of HIV Infection Dual therapies without NRTIs Jean-Guy Baril, MD Clinique médicale du Quartier Latin CHUM This.
M ANAGING ARV REGIMEN FAILURE IN THE HIV INFECTED CHILD Dr L Keet Centre of Excellence HIV Directorate.
Review of HIV and Opportunistic Infections (OI) in Children
Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.
Nuevos fármacos Pere Domingo Malalties Infeccioses Hospital de la Santa Creu i Sant Pau
IAS–USA Managing Antiretroviral Failure in 2012 Jennifer Hoy, MD Professor of Medicine Director, HIV Medicine The Alfred Hospital FINAL: Presented.
Women and Adolescents Case Presentations Vivian M Tamayo-Agrait, MD, FACOG, AAHIVMS Department of Obstetrics and Gynecology University of Puerto Rico Faculty,
Wednesday, May 15 th 1:00 p.m. – 1:30 p.m.. Dr. I. Jean Davis, PhD, DC, PA, AAHIVS.
IAS–USA Choosing the Initial Antiretroviral Regimen Paul A. Volberding, MD Professor of Medicine University of California San Francisco FINAL:
Prescription and Use of Paediatric Antiretroviral Drugs (ARVs) for the Treatment of HIV in Children.
ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified
Summary of ARV prescribing guidelines in London These slides summarise the recommendations by the London HIV Consortium for prescribing antiretrovirals.
PROBLEM BASED LEARNING
Introduction to ARV therapy
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Nurses SOAR! Training Curricula Series For More Information and Inquiries:
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
1 Starting ART in the Context of Opportunistic Infections HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Case 1: 23-year-old Male Student Clinical Director, Division of Infectious Diseases Brigham and Women’s Hospital Professor of Medicine Harvard Medical.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Clinicopathologic Conference Advanced Update in HIV Medicine and Clinical Research October 1, 2009 Tammy M. Meyers, BA, MBBCh (WITS), FCPaed (SA), Mmed,
The Pregnancy Journey Open discussion. HIV and AIDS 2013 Romania Cumulative number people diagnosed with HIV since ,261 (of which 9,946 diagnosed.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Prophylaxis of Opportunistic Infections
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
Case I A 47 old male presents to your office for a yearly checkup. He smokes 40 cigarette/day, and examination detect wheezy chest and bronchospasm. His.
1 Communicating to Other Health Professionals About Your Patient: Doing Case Presentations HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Management of NRTI Resistance
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.
Case 4: 65-year-old Man Newly Diagnosed, Has Other Health Issues Paul E. Sax, MD Clinical Director, Division of Infectious Diseases Brigham and Women’s.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
Internal Medicine Workshop Series Laos September /October 2009.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
#AIDS2016 Dolutegravir (DTG) plus Rilpivirine (RPV) in Suppressed Heavily Pretreated HIV-Infected Patients A. Díaz, J.L. Casado, F.
Switch to PI/r monotherapy
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
HIV Part Dos By Alaina Darby.
Optimizing Antiretorviral Therapy for Long-Term HIV Care
HIV Tutoring By Alaina Darby.
EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC ACTG 5202
Switch from TDF-based to Elvitegravir-Cobicistat-TAF-FTC Study 109
Pharmacokinetics: HIV Drugs
Updated DHHS Adult and Adolescent HIV Treatment Guidelines: Conversation with Dr. Paul Sax Presentation prepared by: Paul Sax, MD and Brian Wood, MD.
ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:
Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort.
Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5
Pharmacokinetics: HIV Drugs
Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II
Adult Guidelines Pretoria, Saturday 17th February 2018
Why Dolutegravir? Daniel R. Kuritzkes, M.D.
Switch to DRV/r monotherapy
Internal Medicine Workshop Series Laos September /October 2009
Diagnosis and Management of HIV-2 in Adults
Presentation transcript:

Case 2: 40-year-old Woman with Long-standing HIV Infection Paul E. Sax, MD Clinical Director, Division of Infectious Diseases Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, MA

40-year-old Woman with Long-standing HIV Infection 40-year-old woman with long-standing HIV infection develops flank pain and hematuria Seen in the ER and diagnosed with nephrolithiasis After IV hydration and pain control, discharged in stable condition   At follow-up 3 days later, has completely recovered   Diagnosed as HIV-positive 10 years prior during pregnancy 2 2

40-year-old Woman with Long-standing HIV Infection Treated with AZT/3TC and LPV/r during pregnancy After delivering child in 2005, she was changed to TDF/FTC, ATV/r once daily, which she has tolerated well thus far Other medical problems include obesity, hypertension controlled with thiazide diuretic, and depression, for which she takes citalopram She smokes 1/2 pack of cigarettes/day Does not drink or use drugs 3 3

40-year-old Woman with Long-standing HIV Infection Do you think the nephrolithiasis is due to atazanavir? Yes No 4 4

40-year-old Woman with Long-standing HIV Infection Question to consider: How would you prove this? 5 5

40-year-old Woman with Long-standing HIV Infection She is quite happy taking the current regimen. Would you encourage her to switch? Yes No 6 6

40-year-old Woman with Long-standing HIV Infection Question to consider: Why / why not? 7 7

40-year-old Woman with Long-standing HIV Infection If she switches treatment, what regimen would you choose? FTC / RPV / TDF (Eviplera, Complera) TDF / FTC / EFV (Atripla) TDF / FTC / EVG / COBI (Stribild) DTG-based regimen RTV-boosted PI monotherapy Maraviroc-containing regimen Other 8 8

Case 3: 46-year-old Man with Untreated HIV Infection Paul E. Sax, MD Clinical Director, Division of Infectious Diseases Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, MA

46-year-old Man with Untreated HIV Infection 46-year-old man admitted with fever and shortness of breath  Diagnosed as HIV positive 3 years before this admission when he was found to have leukopenia and anemia At that time, CD4 cell count = 110; HIV RNA = 77,000; no baseline resistance Antiretroviral therapy was recommended, but the patient did not believe the results of the blood tests since he felt completely well, and he never filled the prescriptions 10 10

46-year-old Man with Untreated HIV Infection During this current hospitalization, he is diagnosed with Pneumocystis pneumonia and treated with high-dose trimethoprim/sulfamethoxazole and prednisone CD4 cell count on admission = 10 HIV RNA = 940,000 cop/mL Hospital day 5, he is started on ART with TDF/FTC and raltegravir   11 11

46-year-old Man with Untreated HIV Infection After a 14-day hospitalization, he is discharged home with plans for close follow-up Fails to show up for his first appointment Arrives unannounced in clinic 1 month after discharge complaining of dysphagia Reports intermittent compliance with his ART regimen Examination demonstrates extensive oral candidiasis CD4 cell count = 40 HIV RNA = 80,000 A resistance genotype demonstrates M184V (3TC and FTC resistance) and N155H (raltegravir resistance) 12 12

46-year-old Man with Untreated HIV Infection Question to consider: What are some strategies to manage patients whose belief systems are at odds with our medical recommendations? 13 13

46-year-old Man with Untreated HIV Infection What regimen would you recommend for this patient? FTC / RPV / TDF (Eviplera, Complera) TDF / FTC / EFV (Atripla) TDF / FTC / EVG / COBI (Stribild) DTG + TDF / FTC Protease inhibitor + TDF / FTC regimen Other 14 14

46-year-old Man with Untreated HIV Infection Question to consider: What supports would you put in place to help maximize the chances of treatment success? 15 15